|
1
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Osmani L, Askin F, Gabrielson E and Li QK:
Current WHO guidelines and the critical role of immunohistochemical
markers in the subclassification of non-small cell lung carcinoma
(NSCLC): Moving from targeted therapy to immunotherapy. Semin
Cancer Biol. 52:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, Bondarenko I, Luft A, Serwatowski
P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM and Lynch
TJ: Ipilimumab in combination with paclitaxel and carboplatin as
first-line therapy in extensive-disease-small-cell lung cancer:
Results from a randomized, double-blind, multicenter phase 2 trial.
Ann Oncol. 24:75–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Horinouchi H, Nishio M, Hida T, Nakagawa
K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M,
et al: Three-year follow-up results from phase II studies of
nivolumab in Japanese patients with previously treated advanced
non-small cell lung cancer: Pooled analysis of ONO-4538-05 and
ONO-4538-06 studies. Cancer Med. 8:5183–5193. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hellmann MD, Rizvi NA, Goldman JW,
Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ,
Juergens RA, et al: Nivolumab plus ipilimumab as first-line
treatment for advanced non-small-cell lung cancer (CheckMate 012):
Results of an open-label, phase 1, multicohort study. Lancet Oncol.
18:31–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fukumura D, Kloepper J, Amoozgar Z, Duda
DG and Jain RK: Enhancing cancer immunotherapy using
antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol.
15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Datta M, Coussens LM, Nishikawa H, Hodi FS
and Jain RK: Reprogramming the tumor microenvironment to improve
immunotherapy: Emerging strategies and combination therapies. Am
Soc Clin Oncol Educ Book. 39:165–174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li HY, McSharry M, Bullock B, Nguyen TT,
Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC,
Clambey ET and Nemenoff RA: The tumor microenvironment regulates
sensitivity of murine lung tumors to PD-1/PD-L1 antibody blockade.
Cancer Immunol Res. 5:767–777. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao D and Mittal V: The role of
bone-marrow-derived cells in tumor growth, metastasis initiation
and progression. Trends Mol Med. 15:333–343. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mittal V, El Rayes T, Narula N, McGraw TE,
Altorki NK and Barcellos-Hoff MH: The microenvironment of lung
cancer and therapeutic implications. Adv Exp Med Biol. 890:75–110.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Binnewies M, Roberts EW, Kersten K, Chan
V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI,
Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor
immune microenvironment (TIME) for effective therapy. Nat Med.
24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rhee JK, Jung YC, Kim KR, Yoo J, Kim J,
Lee YJ, Ko YH, Lee HH, Cho BC and Kim TM: Impact of tumor purity on
immune gene expression and clustering analyses across multiple
cancer types. Cancer Immunol Res. 6:87–97. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pages F, Galon J, Dieu-Nosjean MC, Tartour
E, Sautes-Fridman C and Fridman WH: Immune infiltration in human
tumors: A prognostic factor that should not be ignored. Oncogene.
29:1093–1102. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Givechian KB, Garner C, Benz S, Song B,
Rabizadeh S and Soon-Shiong P: An immunogenic NSCLC
microenvironment is associated with favorable survival in lung
adenocarcinoma. Oncotarget. 10:1840–1849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patel SJ, Sanjana NE, Kishton RJ,
Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM,
Yamamoto TN, et al: Identification of essential genes for cancer
immunotherapy. Nature. 548:537–542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brown SD, Warren RL, Gibb EA, Martin SD,
Spinelli JJ, Nelson BH and Holt RA: Neo-antigens predicted by tumor
genome meta-analysis correlate with increased patient survival.
Genome Res. 24:743–750. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lyssiotis CA and Kimmelman AC: Metabolic
interactions in the tumor microenvironment. Trends Cell Biol.
27:863–875. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Botling J, Edlund K, Lohr M, Hellwig B,
Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et
al: Biomarker discovery in non-small cell lung cancer: Integrating
gene expression profiling, meta-analysis, and tissue microarray
validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie Y, Xiao G, Coombes KR, Behrens C,
Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, et al:
Robust gene expression signature from formalin-fixed
paraffin-embedded samples predicts prognosis of non-small-cell lung
cancer patients. Clin Cancer Res. 17:5705–5714. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ito K and Murphy D: Application of ggplot2
to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol.
2:e792013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tokumo M, Toyooka S, Kiura K, Shigematsu
H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, et al:
The relationship between epidermal growth factor receptor mutations
and clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
29
|
Priedigkeit N, Watters RJ, Lucas PC,
Basudan A, Bhargava R, Horne W, Kolls JK, Fang Z, Rosenzweig MQ,
Brufsky AM, et al: Exome-capture RNA sequencing of decade-old
breast cancers and matched decalcified bone metastases. JCI
Insight. 2:957032017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shah N, Wang P, Wongvipat J, Karthaus WR,
Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, et
al: Regulation of the glucocorticoid receptor via a BET-dependent
enhancer drives antiandrogen resistance in prostate cancer. ELife.
6:e278612017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alonso MH, Ausso S, Lopez-Doriga A,
Cordero D, Guinó E, Solé X, Barenys M, de Oca J, Capella G, Salazar
R, et al: Comprehensive analysis of copy number aberrations in
microsatellite stable colon cancer in view of stromal component. Br
J Cancer. 117:421–431. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jia D, Li S, Li D, Xue H, Yang D and Liu
Y: Mining TCGA database for genes of prognostic value in
glioblastoma microenvironment. Aging (Albany NY). 10:592–605. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang S, Liu T, Nan H, Wang Y, Chen H,
Zhang X, Zhang Y, Shen B, Qian P, Xu S, et al: Comprehensive
analysis of prognostic immune-related genes in the tumor
microenvironment of cutaneous melanoma. J Cell Physiol.
235:1025–1035. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Al-Shibli KI, Donnem T, Al-Saad S, Persson
M, Bremnes RM and Busund LT: Prognostic effect of epithelial and
stromal lymphocyte infiltration in non-small cell lung cancer. Clin
Cancer Res. 14:5220–5227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Berghmans T, Sculier JP and Klastersky J:
A prospective study of infections in lung cancer patients admitted
to the hospital. Chest. 124:114–120. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hattar K, Reinert CP, Sibelius U,
Gökyildirim MY, Subtil FSB, Wilhelm J, Eul B, Dahlem G, Grimminger
F, Seeger W and Grandel U: Lipoteichoic acids from staphylococcus
aureus stimulate proliferation of human non-small-cell lung cancer
cells in vitro. Cancer Immunol Immunother. 66:799–809. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang L, Li M, Deng B, Dai N, Feng Y, Shan
J, Yang Y, Mao C, Huang P, Xu C and Wang D: HLA-DQB1 expression on
tumor cells is a novel favorable prognostic factor for relapse in
early-stage lung adenocarcinoma. Cancer Manag Res. 11:2605–2616.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Itakura M, Terashima Y, Shingyoji M, Yokoi
S, Ohira M, Kageyama H, Matui Y, Yoshida Y, Ashinuma H, Moriya Y,
et al: High CC chemokine receptor 7 expression improves
postoperative prognosis of lung adenocarcinoma patients. Br J
Cancer. 109:1100–1108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leach DR, Krummel MF and Allison JP:
Enhancement of antitumor immunity by CTLA-4 blockade. Science.
271:1734–1736. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Krucken J, Stamm O, Schmitt-Wrede HP,
Mincheva A, Lichter P and Wunderlich F: Spleen-specific expression
of the malaria-inducible intronless mouse gene imap38. J Biol Chem.
274:24383–24391. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chadwick N, Zeef L, Portillo V, Boros J,
Hoyle S, van Doesburg JC and Buckle AM: Notch protection against
apoptosis in T-ALL cells mediated by GIMAP5. Blood Cells Mol Dis.
45:201–209. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Webb LM, Datta P, Bell SE, Kitamura D,
Turner M and Butcher GW: GIMAP1 Is essential for the survival of
naive and activated B cells in vivo. J Immunol. 196:207–216. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Brigl M and Brenner MB: CD1: Antigen
presentation and T cell function. Annu Rev Immunol. 22:817–890.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hayakawa Y, Godfrey DI and Smyth MJ:
Alpha-galactosylceramide: Potential immunomodulatory activity and
future application. Curr Med Chem. 11:241–252. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bagchi S, Li S and Wang CR:
CD1b-autoreactive T cells recognize phospholipid antigens and
contribute to antitumor immunity against a CD1b(+) T cell lymphoma.
Oncoimmunology. 5:e12139322016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vazquez Rodriguez G, Abrahamsson A, Jensen
LD and Dabrosin C: Estradiol promotes breast cancer cell migration
via recruitment and activation of neutrophils. Cancer Immunol Res.
5:234–247. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gatault S, Delbeke M, Driss V, Sarazin A,
Dendooven A, Kahn JE, Lefèvre G and Capron M: IL-18 is involved in
eosinophil-mediated tumoricidal activity against a colon carcinoma
cell line by upregulating LFA-1 and ICAM-1. J Immunol.
195:2483–2492. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wohler J, Bullard D, Schoeb T and Barnum
S: LFA-1 is critical for regulatory T cell homeostasis and
function. Mol Immunol. 46:2424–2428. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mannion BA, Berditchevski F, Kraeft SK,
Chen LB and Hemler ME: Transmembrane-4 superfamily proteins CD81
(TAPA-1), CD82, CD63, and CD53 specifically associated with
integrin alpha 4 beta 1 (CD49d/CD29). J Immunol. 157:2039–2047.
1996.PubMed/NCBI
|
|
50
|
Lee H, Bae S, Jang J, Choi BW, Park CS,
Park JS, Lee SH and Yoon Y: CD53, a suppressor of inflammatory
cytokine production, is associated with population asthma risk via
the functional promoter polymorphism −1560 C>T. Biochim Biophys
Acta. 1830:3011–3018. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mollinedo F, Fontan G, Barasoain I and
Lazo PA: Recurrent infectious diseases in human CD53 deficiency.
Clin Diagn Lab Immunol. 4:229–231. 1997. View Article : Google Scholar : PubMed/NCBI
|
